Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06323824 · ClinicalTrials.gov registry record · Phase 4

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

A Phase 4 study of Opioid Use Disorder, sponsored by Yale University.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target
6
Study locations

NCT06323824: Recruiting Phase 4 study of Opioid Use Disorder, sponsored by Yale University.

NCT06323824 is a Phase 4 study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 600 participants, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06323824, a Phase 4 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.

Primary Outcome

MOUD dispensed to the participant including medication, duration of prescription and daily dose prescribed data will be extracted from the state prescription drug monitoring program (PDMP) and the electronic medical record (EMR).

Conditions Studied

Interventions

  • DRUG Methadone
  • DRUG Buprenorphine (BUP)

Study Locations (6)

California

  • Highland Hospital Bridge Clinic at Alameda Health System - Oakland
  • Outpatient Buprenorphine Induction Clinic, University of California, San Francisco - San Francisco

Colorado

  • Rapid Start Clinic, Kaiser Permanente Colorado - Denver

Massachusetts

  • Officed Based Addiction Treatment Program, Boston Medical Center - Boston

Minnesota

  • Hennepin Healthcare Addiction Medicine - Minneapolis

West Virginia

  • Marshall University Division of Addiction Sciences P.R.O.A.C.T - Huntington

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2024-06-04
Est. Completion 2029-05
Phase Phase 4
Yale University

1,492 total trials

What NCT06323824 shows while recruiting

NCT06323824 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Methadone is the first listed.

NCT06323824 lists 6 locations in 5 states (California, Colorado, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06323824 about?

NCT06323824 is a clinical study titled "Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.". The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based meth...

What is the current status of trial NCT06323824?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2024-06-04. Estimated completion is 2029-05.

What conditions does trial NCT06323824 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06323824?

The interventions under investigation include: Methadone (DRUG), Buprenorphine (BUP) (DRUG).

Who is sponsoring clinical trial NCT06323824?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06323824 being conducted?

This trial has 6 study locations across California, Colorado, Massachusetts, Minnesota, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06323824's enrollment target sits among peer trials

600 27th of 257 higher than 228 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06323824, the US trial registry maintained by the National Library of Medicine. NCT06323824 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.